Jane Street
PCRX icon

Jane Street’s Pacira BioSciences PCRX Stock Holding History

Jane Street’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-140,247
Closed -$3.32M – 12727
2026
Q1 		$3.17M Sell
140,247
-245,737
-64% -$5.46M ﹤0.01% 4249
2025
Q4 		$9.99M Buy
385,984
+239,315
+163% +$5.69M ﹤0.01% 2319
2025
Q3 		$3.78M Sell
146,669
-14,349
-9% -$352K ﹤0.01% 3849
2025
Q2 		$3.85M Sell
161,018
-183,140
-53% -$4.62M ﹤0.01% 3368
2025
Q1 		$8.55M Buy
344,158
+253,484
+280% +$6.07M ﹤0.01% 2190
2024
Q4 		$1.71M Buy
90,674
+68,517
+309% +$1.2M ﹤0.01% 4401
2024
Q3 		$333K Sell
22,157
-58,773
-73% -$1M ﹤0.01% 7848
2024
Q2 		$2.32M Sell
80,930
-106,601
-57% -$3.03M ﹤0.01% 4231
2024
Q1 		$5.48M Buy
187,531
+177,557
+1,780% +$5.45M ﹤0.01% 2493
2023
Q4 		$337K Sell
9,974
-25,527
-72% -$747K ﹤0.01% 7438
2023
Q3 		$1.09M Sell
35,501
-45,756
-56% -$1.65M ﹤0.01% 5051
2023
Q2 		$3.26M Buy
81,257
+30,608
+60% +$1.27M ﹤0.01% 3359
2023
Q1 		$2.07M Buy
50,649
+2,263
+5% +$90K ﹤0.01% 3761
2022
Q4 		$1.87M Buy
48,386
+37,386
+340% +$1.82M ﹤0.01% 3967
2022
Q3 		$585K Sell
11,000
-21,101
-66% -$1.17M ﹤0.01% 6395
2022
Q2 		$1.87M Buy
32,101
+16,857
+111% +$1.1M ﹤0.01% 4297
2022
Q1 		$1.16M Sell
15,244
-5,167
-25% -$344K ﹤0.01% 5815
2021
Q4 		$1.23M Buy
20,411
+11,416
+127% +$629K ﹤0.01% 5487
2021
Q3 		$504K Sell
8,995
-6,487
-42% -$374K ﹤0.01% 7265
2021
Q2 		$940K Buy
15,482
+12,582
+434% +$796K ﹤0.01% 5972
2021
Q1 		$203K Sell
2,900
-3,427
-54% -$245K ﹤0.01% 8244
2020
Q4 		$379K Sell
6,327
-1,155
-15% -$67.6K ﹤0.01% 6104
2020
Q3 		$450K Buy
7,482
+3,361
+82% +$195K ﹤0.01% 5316
2020
Q2 		$216K Buy
+4,121
New +$172K ﹤0.01% 6271
2020
Q1 		– Sell
-10,860
Closed -$492K – 5804
2019
Q4 		$492K Buy
+10,860
New +$461K ﹤0.01% 3708
2019
Q1 		– Sell
-18,798
Closed -$809K – 5456
2018
Q4 		$809K Buy
18,798
+5,236
+39% +$244K ﹤0.01% 2862
2018
Q3 		$667K Buy
+13,562
New +$586K ﹤0.01% 3270
2018
Q1 		– Sell
-10,968
Closed -$501K – 5252
2017
Q4 		$501K Buy
+10,968
New +$435K ﹤0.01% 3171
2017
Q3 		– Sell
-6,064
Closed -$289K – 4909
2017
Q2 		$289K Sell
6,064
-4,804
-44% -$223K ﹤0.01% 3631
2017
Q1 		$496K Sell
10,868
-8,239
-43% -$356K ﹤0.01% 2889
2016
Q4 		$617K Sell
19,107
-697
-4% -$23.3K ﹤0.01% 2619
2016
Q3 		$678K Buy
+19,804
New +$776K ﹤0.01% 2434
2016
Q2 		– Sell
-4,295
Closed -$228K – 4450
2016
Q1 		$228K Sell
4,295
-11,084
-72% -$648K ﹤0.01% 3549
2015
Q4 		$1.18M Buy
+15,379
New +$871K 0.01% 1577
2015
Q1 		– Sell
-4,246
Closed -$376K – 3390
2014
Q4 		$376K Sell
4,246
-3,739
-47% -$354K ﹤0.01% 1699
2014
Q3 		$774K Sell
7,985
-7,907
-50% -$769K 0.01% 1095
2014
Q2 		$1.46M Buy
15,892
+10,742
+209% +$818K 0.02% 691
2014
Q1 		$360K Buy
+5,150
New +$350K ﹤0.01% 1834

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street's PCRX Position: Q2 2026 in Review

Jane Street sold out of Pacira BioSciences (PCRX) in Q2 2026, closing a stake of 140,247 shares — an estimated $3.32M sold.

Jane Street first reported a position in PCRX in Q1 2014 and held it in 38 quarters. The position peaked at $9.99M in Q4 2025. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Jane Street reported no remaining Pacira BioSciences position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 140,247 Pacira BioSciences shares in Q2 2026, an estimated $3.32M.
  • Jane Street first reported a position in Pacira BioSciences in Q1 2014 and held it in 38 quarters.
  • Jane Street's Pacira BioSciences position peaked at $9.99M in Q4 2025.
  • 253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.